Artivion (NYSE:AORT) Price Target Raised to $58.00

Artivion (NYSE:AORT) had its price target boosted by Needham & Company LLC from $50.00 to $58.00 in a research report released on Friday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other analysts have also recently commented on the stock. Wall Street Zen upgraded shares of Artivion from a “hold” rating to a “buy” rating in a research note on Monday, August 25th. JMP Securities increased their price target on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Oppenheimer restated an “outperform” rating on shares of Artivion in a research report on Friday, August 8th. Canaccord Genuity Group lifted their price objective on Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a report on Monday, September 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artivion in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $49.11.

Artivion Trading Down 5.6%

Shares of AORT stock opened at $44.82 on Friday. Artivion has a twelve month low of $21.97 and a twelve month high of $47.69. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52. The business’s 50 day moving average is $42.44 and its two-hundred day moving average is $35.57. The company has a market capitalization of $2.11 billion, a P/E ratio of -106.72 and a beta of 1.65.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion’s quarterly revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities analysts forecast that Artivion will post 0.37 EPS for the current year.

Insider Activity at Artivion

In other news, CEO James P. Mackin sold 12,500 shares of Artivion stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $42.32, for a total transaction of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares in the company, valued at approximately $36,089,776.56. This trade represents a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the business’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $44.02, for a total value of $801,164.00. Following the sale, the senior vice president directly owned 64,200 shares in the company, valued at $2,826,084. This trade represents a 22.09% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 74,858 shares of company stock worth $3,250,129 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Artivion

Several hedge funds and other institutional investors have recently bought and sold shares of AORT. Principal Financial Group Inc. boosted its position in Artivion by 2.4% during the first quarter. Principal Financial Group Inc. now owns 206,777 shares of the company’s stock worth $5,083,000 after purchasing an additional 4,749 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Artivion by 104.2% in the first quarter. New York State Common Retirement Fund now owns 83,754 shares of the company’s stock valued at $2,059,000 after buying an additional 42,737 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Artivion during the 1st quarter worth $3,162,000. MCF Advisors LLC boosted its position in shares of Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after buying an additional 614 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Artivion by 18.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,358 shares of the company’s stock worth $353,000 after buying an additional 2,285 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.